FDA head: Generic biotech drugs may not have to go through trials

12/15/2003 | Reuters

The FDA is studying whether it has the authority to approve generic versions of biotech drugs once the brand-name patents expire and without subjecting the generics to the same lengthy clinical trials. Commissioner Mark McClellan said the agency will soon put the notion forth as a proposal for public comment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID